Q-omics provides the consensus-scored CDC23 profile across patient tissues and cancer cell-line models. CDC23 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDC23 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, CDC23 protein abundance shows 21,369 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRC, HNSC, and PDAC as cancer lineages where CDC23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDC23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDC23 survival associations across molecular data types. CDC23 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDC23 RNA expression–survival associations across cancer types. High CDC23 expression shows unfavorable associations in UVM, MESO, KICH and LIHC, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDC23 RNA expression.
This table summarizes CDC23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDC23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDC23 shows lower tumor expression in THCA and higher tumor expression in HNSC, LIHC, BLCA, KIRC and COAD. The HNSC box plot shows higher CDC23 RNA expression in tumor versus normal tissue (log2 FC = +0.694, t-test p < 0.001).
This table shows molecular features associated with CDC23 in patient tissues and cancer cell lines. In patient samples, CDC23 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDC23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
